# TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

> **NCT05275998** · PHASE1,PHASE2 · COMPLETED · sponsor: **TaiMed Biologics Inc.** · enrollment: 51 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** TMB-365/TMB-380

## Key facts

- **NCT ID:** NCT05275998
- **Lead sponsor:** TaiMed Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2024-11-20
- **Final completion:** 2024-11-20
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275998, "TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05275998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*